Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Kelly

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Blood|February 21, 2015
Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiencyYasser M El-Sherbiny, Gina M Doody, Richard J Kelly, et al.
Research and Practice in Thrombosis and Haemostasis|May 30, 2024
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settingsRichard J Kelly, Hisakazu Nishimori, Regina Horneff, et al.
The Journal of Arthroplasty|October 22, 2017
A Comparison of Walking Gait Following Mechanical and Kinematic Alignment in Total Knee Joint ReplacementPeter J McNair, Mark G Boocock, Nicholas D Dominick, et al.
Leukemia & Lymphoma|August 18, 2011
Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group studyQuentin A Hill, Richard J Kelly, Chetan Patalappa, et al.
Blood Advances|February 5, 2024
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNHMorag Griffin, Richard J Kelly, Jens Panse, et al.
Blood Advances|April 9, 2024
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuriaRégis Peffault de Latour, Morag Griffin, Richard J Kelly, et al.
International Journal of Hematology|December 10, 2013
Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumabSuresh K Krishnan, Anita Hill, Peter Hillmen, et al.
Haematologica|November 28, 2024
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trialMorag Griffin, Shreyans Gandhi, Richard J Kelly, et al.
Ejhaem|May 21, 2025
Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor-Naive Patients With Paroxysmal Nocturnal HaemoglobinuriaMatthew Holt, Richard J Kelly, Jilles M Fermont, et al.
Organic & Biomolecular Chemistry|September 8, 2004
Asymmetric total synthesis of sperabillins B and D via lithium amide conjugate additionStephen G Davies, Jane R Haggitt, Osamu Ichihara, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Blood|February 21, 2015
Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiencyYasser M El-Sherbiny, Gina M Doody, Richard J Kelly, et al.
Research and Practice in Thrombosis and Haemostasis|May 30, 2024
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settingsRichard J Kelly, Hisakazu Nishimori, Regina Horneff, et al.
The Journal of Arthroplasty|October 22, 2017
A Comparison of Walking Gait Following Mechanical and Kinematic Alignment in Total Knee Joint ReplacementPeter J McNair, Mark G Boocock, Nicholas D Dominick, et al.
Leukemia & Lymphoma|August 18, 2011
Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group studyQuentin A Hill, Richard J Kelly, Chetan Patalappa, et al.
Blood Advances|February 5, 2024
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNHMorag Griffin, Richard J Kelly, Jens Panse, et al.
Blood Advances|April 9, 2024
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuriaRégis Peffault de Latour, Morag Griffin, Richard J Kelly, et al.
International Journal of Hematology|December 10, 2013
Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumabSuresh K Krishnan, Anita Hill, Peter Hillmen, et al.
Haematologica|November 28, 2024
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trialMorag Griffin, Shreyans Gandhi, Richard J Kelly, et al.
Ejhaem|May 21, 2025
Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor-Naive Patients With Paroxysmal Nocturnal HaemoglobinuriaMatthew Holt, Richard J Kelly, Jilles M Fermont, et al.
Organic & Biomolecular Chemistry|September 8, 2004
Asymmetric total synthesis of sperabillins B and D via lithium amide conjugate additionStephen G Davies, Jane R Haggitt, Osamu Ichihara, et al.
Pageof 4